AUTHORS
Alex Francisco Herrera, MD, Gilles Salles I, MD, PhD2, Franck Morschhauser3, Laurie H. Sehn, MD4, Jonathan W. Friedberg, MD5, Hervé Tilly, MD, PhD6, Christopher R. Flowers Jr, MD, MS7, Georg Lenz, MD8, Jeff Sharman, MD9, Charles Herbaux, MD, PhD10, John M. Burke, MD11, Matthew J Matasar, MD, MS12, Graham P. Collins, BM13, Neha Mehta-Shah, MD, MSCI14, Lucie Oberic15, Adrien Chauchet, MD16, Wojciech Jurczak, MD, PhD17, Yuqin Song, MD18, Antonio Pinto, MD19, Shinya Rai, MD, PhD20, Koji Izutsu, MD, PhD21, Thomas Melchardt, MD22, Larysa Nogaieva, MD23, Juan M. Bergua-Burgués, MD24, Matthew C. Cheung, MD, SM, FRCPC25, Dok Hyun Yoon, MD26, Greg Hapgood27, Eduardo Munhoz28, Jyh-Pyn Gau29, Muhit Özcan Sr, MD30, Frank Stenner Liewen, MD31, Marie Deprez32, Lisa Musick, PharmD33, Wilfred Leung, PhD, DVM34, Matthew Sugidono, PharmD35, Yanwen Jiang, PhD36, Connie Batlevi37, Mark Yan, PhD38, Marek Trnený, MD, CSc, Prof.39
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 University of Lille, Lille, France
4 BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada
5 Wilmot Cancer Institute, University of Rochester, Rochester, New York, United States
6 Centre Henri-Becquerel and University of Rouen, Rouen, France
7 M.D. Anderson Cancer Center, Houston, Texas, United States
8 University Hospital Münster, Department of Medicine A – Haematology and Oncology, Münster, Germany
9 Willamette Valley Cancer Institute and Research Center, Florence, Oregon, United States
10 University of Montpellier, Montpellier, France
11 Rocky Mountain Cancer Centers/US Oncology, Aurora, Colorado, United States
12 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
13 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
14 Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States
15 Department of Hematology, Cancer University Institute, CHU Toulouse, Toulouse, France
16 Department of Hematology, Besançon University Hospital, Besançon, France
17 Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland
18 Peking University Cancer Hospital, Beijing, China
19 Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy
20 Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City, Japan
21 National Cancer Center Hospital, Tokyo, Japan
22 Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Cancer Research Laboratory of the Department of Internal Medicine III Paracelsus Medical University, Salzburg, Austria
23 Clinical Center of Oncology, Hematology, Transplantation and Palliative Care of Cherkasy Regional Council, Cherkasy, Ukraine
24 Servicio de Hematologia y Hemoterapia, Hospital San Pedro de Alcántara, Cáceres, Spain
25 Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
26 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Rep. of South
27 Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia
28 Hospital Erasto Gaertner, Curitiba, Brazil
29 Taipei Veterans General Hospital, Taipei, Taiwan
30 Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
31 Department of Oncology, University Hospital Basel, Basel, Switzerland
32 F. Hoffmann-La Roche Ltd, Basel, Switzerland
33 Genentech, Inc., South San Francisco, California, United States
34 Genentech, Inc., South San Francisco, California, United States
35 Genentech, Inc., South San Francisco, California, United States
36 Genentech, Inc., South San Francisco, California, United States
37 Genentech, Inc., South San Francisco, California, United States
38 Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada
39 Charles University, Prague, Czech Republic
ABSTRACT
Background: In the POLARIX study (NCT03274492), Pola-R-CHP showed a significant progression-free survival benefit vs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients (pts) with diffuse large B-cell lymphoma (DLBCL) and International Prognostic Index (IPI) score of ≥2 at the 2-year analysis (Tilly, et al. N Eng J Med 2022), which was sustained after 5 years of follow up (Morschhauser, et al. J Clin Oncol 2025). Here, we report the results of the final analysis after 7 years of follow-up (cut-off, May 6, 2026).
Methods: Pts (18–80 years) were randomized 1:1 to receive six cycles of Pola-R-CHP or R-CHOP, plus two cycles of rituximab (Tilly, et al. N Eng J Med 2022). In this analysis, 1000 pts (expanded population) were evaluated, including 879 pts from the global intention-to-treat (ITT) population and 121 pts from the Chinese extension cohort. Overall survival (OS), long-term safety, and new anti-lymphoma therapy (NALT) are described as post-hoc exploratory analyses. A competing risk analysis assessed the risk of lymphoma-related death, with non-lymphoma-related deaths treated as competing events, vs other causes.
Results: In the global ITT population, 879 (Pola-R-CHP, n=440; R-CHOP, n=439) pts were evaluable for efficacy and 873 (Pola-R-CHP, n=435; R-CHOP, n=438) for safety. Median duration of survival follow-up was 84.8 months, with 7-year OS estimates of 77.8% (95% confidence interval [CI]: 73.8–81.8) for Pola-R-CHP vs 74.4% (95% CI: 70.1–78.7) for R-CHOP (hazard ratio [HR], 0.87 [95% CI: 0.66–1.15]), consistent with the 5-year analysis. OS subgroup analyses showed a trend towards favorable outcomes for Pola-R-CHP in multiple high-risk subgroups, including pts with an IPI score of 3–5 (HR, 0.82 [95% CI: 0.60–1.14]) and activated B-cell (ABC) DLBCL by gene expression profiling (HR, 0.49 [95% CI: 0.29–0.83]). Pola-R-CHP showed numerically favorable 7-year OS outcomes across IPI 3–5 and cell-of-origin subgroups (IPI 3–5 and ABC DLBCL: HR, 0.38 [95% CI: 0.21–0.71]; IPI 3–5 and germinal center B-cell DLBCL: HR, 0.87 [95% CI: 0.52–1.48]). In total, 203 deaths were observed; 95 (21.6%) with Pola-R-CHP and 108 (24.6%) with R-CHOP. Fewer pts received NALT with Pola-R-CHP vs R-CHOP (26.6% vs 36.2%, respectively), consistent with a lower incidence of disease progression. Of those who received NALT, 25% fewer pts treated with Pola-R-CHP required subsequent therapies vs pts treated with R-CHOP (37.5% vs 62.5%).
For Pola-R-CHP vs R-CHOP, lymphoma-related deaths occurred in 56 (12.7%) vs 71 (16.2%) pts, respectively (during the first 5 years: 47 vs 55 pts; beyond 5 years: 9 vs 16 pts). The incidence of death from infection (1.6% vs 2.7%), cardiovascular disease (1.1% vs 0.9%), and secondary malignancy (2.0% vs 1.6%) was similar across treatment arms. In the competing risk analysis, the cumulative incidences of lymphoma-related death for Pola-R-CHP vs R-CHOP were: 7.6% vs 7.5% at 2 years (Δ=0.09%); 10.9% vs 13.1% at 5 years (Δ=−2.1%); 13.1% vs 16.8% at 7 years (Δ=−3.6%).
In the expanded population, 1000 (Pola-R-CHP, n=500; R-CHOP, n=500) pts were evaluable for efficacy and 993 (Pola-R-CHP, n=495; R-CHOP, n=498) for safety. Results in the expanded population (median duration of survival follow-up: 84.1 months) were generally consistent with the global population with 7-year OS estimates of 77.8% (95% CI: 74.0–81.6) for Pola-R-CHP vs 74.2% (95% CI: 70.1–78.3) for R-CHOP (HR, 0.86 [95% CI: 0.66–1.11]). Lymphoma-related deaths occurred in 64 (12.8%) pts treated with Pola-R-CHP vs 83 (16.6%) with R-CHOP. In the competing risk analysis, the cumulative incidences of lymphoma-related death for Pola-R-CHP vs R-CHOP were: 7.1% vs 8.7% at 2 years (Δ=−1.6%); 11.3% vs 14.0% at 5 years (Δ=−2.7%); 13.4% vs 17.4% at 7 years (Δ=−4.0%).
No new safety signals were observed during long-term follow-up with no additional safety events reported since the 5-year update.
Conclusions: Extended 7-year follow-up of POLARIX demonstrated reassuring OS with Pola-R-CHP vs R-CHOP, with lymphoma-related deaths occurring more frequently in the R-CHOP arm and the difference between treatment arms increasing over time. Safety profiles remained similar between arms and no new safety signals were identified. These long-term outcomes confirm Pola-R-CHP as a standard of care for pts with previously untreated intermediate- or high-risk DLBCL.
DISCLOSURES
Alex Francisco Herrera, MD: Genentech - Research Funding; Pfizer - Research Funding; BMS - Research Funding; Merck - Research Funding; Merck - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Allogene Therapeutics - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)